“Efficacy and Safety of Tralokinumab in US Adults with Moderate-to-Severe Atopic Dermatitis: A Post-hoc Analysis of ECZTRA3” (2023) SKIN The Journal of Cutaneous Medicine, 7(2), pp. 686–695. doi:10.25251/skin.7.2.5.